Glucagon‐like peptide ‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15777 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Muhammad Aaqib Shamim und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Pediatric Obesity, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 80 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To synthesize the evidence on the effects of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in adolescents with overweight or obesity. Materials and Methods For this systematic review and network meta‐analysis, we searched five databases and registries until 2 March 2024 for eligible randomized controlled trials (RCTs). The primary outcome was weight change. We did a pairwise meta‐analysis to compare GLP‐1RAs and placebo, followed by a drug‐wise network meta‐analysis (NMA) to compare GLP‐1RAs against each other.
Results
We screened 770 records to include 12 RCTs with 883 participants. The evidence suggests that GLP‐1RAs reduced weight (mean difference −4.21 kg, 95% confidence interval [CI] −7.08 to −1.35) and body mass index (BMI; mean difference −2.11 kg/m 2 , 95% CI −3.60 to −0.62). The evidence on waist circumference, body fat percentage and adverse events (AEs) was very uncertain. The results remained consistent with subgroup analyses for coexisting type 2 diabetes. Longer therapy duration led to a greater reduction in weight and BMI. In the NMA, semaglutide led to the greatest weight reduction, followed by exenatide, liraglutide and lixisenatide.
Conclusions
The evidence suggests that GLP‐1RAs reduce most weight‐related outcomes in adolescents, with semaglutide being the most efficacious. There is uncertain evidence on body fat and serious AEs, probably due to fewer studies and low incidence, respectively. Larger RCTs with head‐to‐head comparisons, pragmatic design, adiposity‐related outcomes, and economic evaluation can further guide the use and choice of GLP‐1RAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India.
- Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Syed Mantaquie Memorial College of Nursing and Medical Technology (SMMCNMT), Islamic University of Science and Technology (IUST), Awantipora, India.
- Department of Nursing, GitaRam College of Nursing, Berhampore, India.
- Department of Pharmacology, Indira Gandhi Institute of Medical Sciences, Patna, India.
- Advanced Pediatric Center, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
ORCID-Profile: Muhammad Aaqib Shamim, Amol N Patil, Ulfat Amin, Tuli Roy, Krishna Tiwari, Jogender Kumar, Santenna Chenchula, Priyanka Rao, Venkata Ganesh, Shoban Babu Varthya, Surjit Singh, Ravindra Shukla, Ashu Rastogi, Aravind P Gandhi, Ranjit Sah, Bijaya Kumar Padhi, Pradeep Dwivedi, Kamlesh Khunti
Zitieren
APA
Shamim, M. A., Patil, A. N., Amin, U., Roy, T., Tiwari, K., Husain, N., Kumar, J., Chenchula, S., Rao, P., Ganesh, V., Varthya, S. B., Singh, S., Shukla, R., Rastogi, A., Gandhi, A. P., Satapathy, P., Sah, R., Padhi, B. K., Dwivedi, P., & Khunti, K. (2024). Glucagon‐like peptide ‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15777
Vancouver
Shamim MA, Patil AN, Amin U, Roy T, Tiwari K, Husain N, et al. Glucagon‐like peptide ‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15777
BibTeX
@article{Shamim2024,
author = {Shamim, Muhammad Aaqib and Patil, Amol N and Amin, Ulfat and Roy, Tuli and Tiwari, Krishna and Husain, Noor and Kumar, Jogender and Chenchula, Santenna and Rao, Priyanka and Ganesh, Venkata and Varthya, Shoban Babu and Singh, Surjit and Shukla, Ravindra and Rastogi, Ashu and Gandhi, Aravind P and Satapathy, Prakisini and Sah, Ranjit and Padhi, Bijaya Kumar and Dwivedi, Pradeep and Khunti, Kamlesh},
title = {Glucagon‐like peptide ‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15777}
}
EUVIMED